Publication | Open Access

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Solid TumorsMedicineImmunologyTumor TargetingFirst-in-human Phase 1Cancer TreatmentImmunotherapyOncologyRadiation OncologyCancer ResearchMolecular Oncology